article thumbnail

Roche joins startup Remix in bet on another way to drug RNA

Bio Pharma Dive

The deal is the third Roche has formed with startups developing pills that target RNA, following similar pacts with Arrakis and Ribometrix.

RNA 177
article thumbnail

Wave readies clinical testing for first RNA editing therapy

Bio Pharma Dive

The biotech, one of several advancing RNA editing medicines, expects to obtain “proof-of-mechanism” data in patients with the inherited disorder alpha-1 antitrypsin deficiency by next year.

RNA 177
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gatehouse Bio and AstraZeneca to develop RNA therapeutics for heart failure

Pharmaceutical Technology

US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). Gatehouse Bio is engaged in developing small RNA-based therapeutics using AI technology.

RNA 246
article thumbnail

Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior

pharmaphorum

billion, adding expertise in RNA therapeutics and a heart failure therapy in mid-stage trials. Novo Nordisk has agreed to buy Cardior Pharmaceuticals for $1.1

RNA 122
article thumbnail

Seattle institute lands $18m funding to develop RNA vaccine for chikungunya

Pharmaceutical Technology

AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.

RNA 244
article thumbnail

Next-generation RNA technologies: making longer-lasting drugs with a broader reach

Bio Pharma Dive

At least 10 biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand.

RNA 332
article thumbnail

Drugging RNA with pills: small molecules for a big frontier

Bio Pharma Dive

A handful of startups have formed in recent years with plans to target RNA with small molecules. Many have caught the attention of big drugmakers.

RNA 294